These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 10955812)

  • 1. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.
    Migaldi M; Sgambato A; Garagnani L; Ardito R; Ferrari P; De Gaetani C; Cittadini A; Trentini GP
    Clin Cancer Res; 2000 Aug; 6(8):3131-8. PubMed ID: 10955794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
    Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
    Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of p53 and p21(waf1/cip1) immunoreactivity in epithelial cancers of the ovary.
    Werness BA; Freedman AN; Piver MS; Romero-Gutierrez M; Petrow E
    Gynecol Oncol; 1999 Dec; 75(3):413-8. PubMed ID: 10600299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
    Zhao XD; Zhang Y; He SR; Yang L
    Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.
    Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE
    Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.
    Baekelandt MM; Holm R; Nesland JM; Tropé CG; Kristensen GB
    Anticancer Res; 2000; 20(2B):1061-7. PubMed ID: 10810398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
    Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
    Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
    ; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A
    Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
    Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
    Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.